Atlas Bio raises $12.5 million for virtual drug trials
Oct 27, 2026
Healthcare
Switchpoint Bio raises $5.3 million for AI epigenomics platform
Nov 11, 2026
Switchpoint Bio raised $5.3 million to develop a platform that uses AI and blood based epigenomic profiling to measure biological changes during treatment.
Switchpoint Bio emerged from stealth with $5.3 million in pre seed financing, including $5 million from Treehouse Delmar Investments, according to Tech.eu. The Helsinki and Cambridge biotech startup is developing an AI platform that measures biological changes during treatment through blood samples.
The platform combines AI with targeted DNA methylation profiling of circulating immune cells. It is designed to identify disease related immune states and track changes after treatment without repeated tissue biopsies.
Switchpoint Bio is testing the approach in autoimmune disease, including systemic lupus erythematosus. The funding will support clinical and industry validation, expansion of clinical and biobank datasets, further platform development, and growth of its scientific and technical teams.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Funding
Nov 11 Mosaic Raises $47M for Blood Vessel Surgery Robots Nov 11 Kardi AI Raises €5.3 Million for Heart Monitoring Expansion Nov 11 Atomarine Raises $19 Million for Floating Nuclear Data Centers Nov 11 Anthropic IPO Bankers Prepare for $1.5 Trillion Valuation After Orders Cover Offering, FT Reports Nov 10 Mercor Raises $750 Million Series D at $20 Billion ValuationMore from Life Sciences
Nov 11 Mosaic Raises $47M for Blood Vessel Surgery Robots Nov 11 Kardi AI Raises €5.3 Million for Heart Monitoring Expansion Nov 10 Google Cloud Launches Gemini for Healthcare With HCA, Northwell and Optum Nov 10 Oura to Buy AI Care Company Counsel Health for $625 Million Nov 10 Dimer Health's AI-supported post-discharge team found unmet care needs in 23% of 680 hospital patientsFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
BioStack Raises $9.5 Million for Medical AI Data Network
Oct 22, 2026
Funding
Illumina Launches BioInsight Platform for Genomic Research
Oct 14, 2026
Biotech
Pathos AI Raises $237 Million at $3 Billion Valuation
Oct 23, 2026
Funding
Lunit and Discovery Life Sciences Partner on AI Tissue Analysis
Oct 12, 2026
Biotech
Isomorphic Labs Seeks $5 Billion at $50 Billion Valuation
Nov 05, 2026
Funding
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.